Effectiveness and Tolerability of Adding Ezetimibe to Niacin-Based Regimens for Treatment of Primary Hyperlipidemia

Jelesoff, Nicole; Ballantyne, Christie M.; Xydakis, Antonios M.; Chiou, Philip; Jones, Peter H.; Guyton, John R.

doi:10.4158/ep.12.2.159

Cited by 19 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that niacin is accompanied by a variety of side effects; of note, in HPS II THRIVE, the combination of niacin and simvastatin was accompanied by an increased risk of myopathy in the Chinese population (HPS2-THRIVE 2013). On the other hand, for patients with statin intolerance, the combination of niacin + ezetimibe can effectively lower LDL-C levels (Jelesoff et al 2006); this represents an alternative to statin therapy but without proof of risk reduction.…”

Section: Lipid Lowering Drugs and Ascvd Riskmentioning

confidence: 99%

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy

2013

Journal of Clinical Lipidology

151

View full text Add to dashboard Cite

Section: Lipid Lowering Drugs and Ascvd Riskmentioning

confidence: 99%

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy

2013

Journal of Clinical Lipidology

151

View full text Add to dashboard Cite

“…The clinical effectiveness of the drug has been shown outside the specialist environment of a clinical trial, with reports from general practice [26] and hospital clinics [27]. There is also emerging evidence that ezetimibe might potentially be usefully combined with a fibrate [28] or niacin [29].…”

Section: Evidence That Ezetimibe Favourably Modifies Lipidsmentioning

confidence: 98%

Role of ezetimibe in the management of patients with atherosclerosis

Hamilton

2009

Coronary Artery Disease

View full text Add to dashboard Cite

Lowering low-density lipoprotein cholesterol is central to the management of patients at risk of atherosclerosis. Traditional treatment has focused on modifying the endogenous lipid pathway using statins. Ezetimibe, a selective inhibitor of cholesterol absorption, has proved to be highly effective in lowering low-density lipoprotein cholesterol, and its use has soared, especially in the United States. Unfortunately, there is currently no evidence proving that treatment with ezetimibe is linked to a reduction in cardiovascular events; therefore, its choice as a drug to lower cholesterol is currently controversial.

show abstract

“…One study evaluated the co-administration of ezetimibe with niacin-based regimens in 58 hypercholesterolaemic patients [262]. Most of the patients (75%) were also on a statin.…”

Section: Iv) Combination With Nicotinic Acidmentioning

confidence: 99%

Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract

Filippatos

Mikhailidis²

2009

CPD

View full text Add to dashboard Cite

This review considers the hypolipidaemic drugs that act on the gastrointestinal (GI) tract. We searched PubMed up to April 2008 and included randomized controlled trials, original papers, review articles and case reports. Bile acid sequestrants (BAS) have a well-established low density lipoprotein cholesterol (LDL-C) lowering effect, but may increase triglyceride (TG) levels. BAS have no systematic adverse effects, but are associated with increased GI adverse effects and interactions with the absorption of other drugs. Ezetimibe improves LDL-C, high density lipoprotein cholesterol and TG levels, as monotherapy or especially when given with a statin. Ezetimibe has not been associated with serious adverse effects. Ezetimibe has not been evaluated in large clinical trials with cardiovascular disease (CVD) endpoints. Phytosterols are not licensed drugs; they have a well-established LDL-C lowering effect, but there are no large long-term randomized clinical trials investigating their effects on CVD events. Orlistat is an antiobesity drug with a small additional LDL-C lowering effect independent of weight loss. Orlistat-assisted weight loss improves the overall lipid profile, carbohydrate metabolism and transaminase activities. However, its use should be limited to weight reduction. This drug is associated with increased GI adverse effects.

show abstract

Effectiveness and Tolerability of Adding Ezetimibe to Niacin-Based Regimens for Treatment of Primary Hyperlipidemia

Cited by 19 publications

References 21 publications

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Role of ezetimibe in the management of patients with atherosclerosis

Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract

Contact Info

Product

Resources

About